Federated Hermes, Inc. Geron Corp Transaction History

Federated Hermes, Inc.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$1.75 - $3.44 $119 - $233	68 Added 0.53%	12,984 $42,000
Q4 2023 Jan 31, 2024	SELL	$1.74 - $2.31 $1,024 - $1,360	-589 Reduced 4.36%	12,916 $27,000
Q3 2023 Nov 13, 2023	BUY	$2.11 - $3.28 $28,495 - $44,296	13,505 New	13,505 $28,000
Q3 2022 Nov 14, 2022	BUY	$1.67 - $2.94 $1 - $2	1 Added 100.0%	2 $1,000
Q2 2022 Aug 15, 2022	BUY	$1.19 - $1.65 $1 - $1	1 New	1 $1,000
Q1 2021 May 13, 2021	SELL	$1.52 - $2.1 $5,931 - $8,194	-3,902 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$1.55 - $2.05 $165 - $219	107 Added 2.82%	3,902 $6,000
Q3 2020 Nov 12, 2020	BUY	$1.59 - $2.19 $6,034 - $8,311	3,795 New	3,795 $7,000
Q3 2018 Nov 13, 2018	SELL	$1.76 - $6.38 $4,350 - $15,771	-2,472 Closed	0 $0
Q2 2018 Aug 10, 2018	BUY	$3.29 - $4.82 $5,106 - $7,480	1,552 Added 168.7%	2,472 $8,000
Q1 2018 May 09, 2018	SELL	$1.81 - $5.98 $647 - $2,140	-358 Reduced 28.01%	920 $4,000
Q3 2017 Nov 13, 2017	BUY	$1.99 - $2.65 $2,543 - $3,386	1,278	1,278 $3,000

306

452M

1.07M

648K

Ticker GERN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 377,819,008
Market Cap $623M
Description
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

Stay updated on Federated Hermes, Inc. with notifications on news.